Clarity Pharmaceuticals マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Michelle Parker

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	less than a year
CEOの所有権	0.3%
経営陣の平均在職期間	2.6yrs
取締役会の平均在任期間	4.9yrs

経営陣の近況

Recent updates

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Sep 23

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Jan 03

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

May 29

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Aug 24

Here's Why We're Not Too Worried About Clarity Pharmaceuticals' (ASX:CU6) Cash Burn Situation

Jan 13

CEO（最高経営責任者

Michelle Parker

less than a year

在職期間

Ms. Michelle Parker is Executive Director of Clarity Pharmaceuticals Ltd from August 2024 and is its Chief Executive Officer and MD. Ms. Parker joined the Clarity Pharmaceuticals Ltd in June 2018. She serv...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Alan Taylor	Executive Chairman	11yrs	AU$1.22m	4.9% A$ 89.1m
David Green	Chief Financial Officer	2.6yrs	AU$273.61k	データなし
Colin Biggin	COO & Non-Independent Executive Director	less than a year	AU$1.02m	1.35% A$ 24.6m
Michelle Parker	CEO, MD & Executive Director	no data	データなし	0.34% A$ 6.1m
Matthew Harris	Chief Scientific Officer	no data	AU$241.43k	1.89% A$ 34.5m
Lisa Sadetskaya	Director of Corporate Communications.	no data	データなし	データなし
Mary Bennett	Head of People & Culture	no data	データなし	データなし
Shaemus Gleason	Executive Vice President of Operations	no data	データなし	データなし
Othon Gervasio	Chief Medical Officer	no data	データなし	データなし
Robert Vickery	Company Secretary	no data	AU$268.69k	データなし

2.6yrs

平均在職期間

経験豊富な経営陣: CU6の経営陣は経験豊富であると考えられます ( 2.6年の平均在職年数)。

取締役

名称	ポジション	在職期間	報酬	所有権
Alan Taylor	Executive Chairman	11yrs	AU$1.22m	4.9% A$ 89.1m
Colin Biggin	COO & Non-Independent Executive Director	5.1yrs	AU$1.02m	1.35% A$ 24.6m
Michelle Parker	CEO, MD & Executive Director	less than a year	データなし	0.34% A$ 6.1m
Christopher Roberts	Non-Executive Director	8.7yrs	AU$86.88k	5.66% A$ 102.9m
Thomas Ramdahl	Non-Executive Director	5.7yrs	AU$86.88k	0.22% A$ 4.1m
Neal Shore	Member of Scientific Advisory Board	2.5yrs	データなし	データなし
Rosanne Robinson	Lead Independent Non-Executive Director	14.1yrs	AU$95.72k	0.056% A$ 1.0m
Jason Lewis	Member of Scientific Advisory Board	no data	データなし	データなし
Oliver Sartor	Member of Scientific Advisory Board	4.7yrs	データなし	データなし
Paul Donnelly	Member of Scientific Advisory Board	no data	データなし	データなし
Andrei Iagaru	Member of Scientific Advisory Board	2.6yrs	データなし	データなし
Louise Emmett	Member of Scientific Advisory Board	2.4yrs	データなし	データなし

4.9yrs

平均在職期間

経験豊富なボード: CU6の取締役会は経験豊富であると考えられます ( 4.9年の平均在任期間)。

Clarity Pharmaceuticals マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

MD, CEO & Executive Director exercised options to buy AU$8.3m worth of stock.

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 20, 2024

Clarity Pharmaceuticals Confirms the Appointment of Ms. Michelle Parker to Its Board, Effective September 20, 2024

MD, CEO & Executive Director exercised options to buy AU$5.6m worth of stock.

Executive Chairman exercised options to buy AU$3.4m worth of stock.

Non-Executive Director exercised options to buy AU$1.1m worth of stock.

Recent updates

No longer forecast to breakeven

Clarity Pharmaceuticals Announces Positive Guidance from the U.S. FDA on 64Cu-SAR-bisPSMA Phase III Trial in Patients with Recurrence of Prostate Cancer

MD, CEO & Executive Director exercised options to buy AU$8.3m worth of stock.

We Think Clarity Pharmaceuticals (ASX:CU6) Can Easily Afford To Drive Business Growth

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 20, 2024

Now 21% overvalued after recent price rise

Clarity Pharmaceuticals Confirms the Appointment of Ms. Michelle Parker to Its Board, Effective September 20, 2024

Clarity Pharmaceuticals Ltd Receives FDA Fast Track Designation for 64Cu-Sar-Bispsma

MD, CEO & Executive Director exercised options to buy AU$5.6m worth of stock.

No longer forecast to breakeven

Executive Chairman exercised options to buy AU$3.4m worth of stock.

No longer forecast to breakeven

No longer forecast to breakeven

Price target increased by 14% to AU$3.87

New minor risk - Shareholder dilution

Clarity Pharmaceuticals Ltd has completed a Follow-on Equity Offering in the amount of AUD 100.64532 million.

Clarity Pharmaceuticals Ltd has filed a Follow-on Equity Offering in the amount of AUD 100.64532 million.

Non-Executive Director exercised options to buy AU$1.1m worth of stock.

Clarity Pharmaceuticals Announces the Successful Completion of Cohort 3 and Advancement to Cohort 4, the First Multi-Dose Cohort in the SECuRE Trial

Clarity Pharmaceuticals Ltd. Announces Additional COBRA Results: SAR-bisPSMA Detects Lesions in the 2-Millimetre Range

New major risk - Financial position

Price target increased by 13% to AU$2.48

Clarity Pharmaceuticals Ltd Announces Resignation of Non-Executive Directors

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Clarity Pharmaceuticals Announces First Patient Dosed in Registrational Phase III Prostate Cancer Trial with Cu-64 SAR-BispsMA

Clarity Pharmaceuticals Ltd. Announces First Patient with Metastatic Prostate Cancer to Receive 2 Doses of Cu-67 SAR-bisPSMA Achieves Undetectable PSA Level

Clarity Pharmaceuticals Ltd Commences Registrational Phase III Clarify Trial in Prostate Cancer

No longer forecast to breakeven

Clarity Pharmaceuticals Announces Successful Completion of First Stage of Cohort 3 of Phase I/IIa Theranostic Trial, SECuRE

Clarity Pharmaceuticals Announces Recruitment Target Achieves for Phase II Sar-Bombesin Prostate Cancer Trial

Clarity Pharmaceuticals and PSI CRO AG Kick Off SAR-BispsMA Phase III

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 23, 2023

Clarity Pharmaceuticals Announces the Dosing of the First Patient in Its Theranostic (64) Cu Sar-Bombesin Phase I/Ii Trial in Metastatic Castrate Resistant Prostate Cancer Trial in Metastatic Castrates Resistant Prostate Cancer (Mcrpc)

Price target increased by 8.5% to AU$1.82

New major risk - Revenue and earnings growth

Clarity Pharmaceuticals Announces Successful Completion of Cohort 2 and Advancement to Cohort 2 of Theranostic Trial, Secure

Clarity Pharmaceuticals Announces Phase II US-Based Diagnostic Cu SAR-Bombesin

New minor risk - Profitability

MD, CEO & Executive Director exercised options to buy AU$493k worth of stock.

Clarity Pharmaceuticals Announces Positive Guidance from US FDA on Cu-64 Sar-Bispsma Phase III Trial in Prostate Cancer

Consensus EPS estimates fall by 13%

We're Interested To See How Clarity Pharmaceuticals (ASX:CU6) Uses Its Cash Hoard To Grow

Consensus revenue estimates increase by 261%

MD, CEO & Executive Director exercised options to buy AU$243k worth of stock.

Clarity Pharmaceuticals Ltd Announces Its Phase II Diagnostic 64 Cu Sartate Trial (Disco NCT04438304)

Clarity Pharmaceuticals Announces PROPELLER Trial Results - SAR-bisPSMA Safe, Well Tolerated and Efficacious in the Detection of Prostate Cancer

Clarity Pharmaceuticals Ltd Announces Diagnostic Prostate Cancer Trial Reaches Recruitment Target

Clarity Pharmaceuticals Ltd Announces Board Changes

Clarity Pharmaceuticals Ltd Announces Positive Topline Results from SAR-bisPSMA Diagnostic Trial

Price target increased to AU$1.54

Clarity Pharmaceuticals Announces IND Approval from the FDA for Theranostic Sar-Bombesin Trial in Prostate Cancer

Less than half of directors are independent

Clarity Pharmaceuticals Ltd Announces 50% Recruitment Milestone Reached for Phase II BOP Prostate Cancer Trial

Clarity Pharmaceuticals Ltd Announces 50% Recruitment Milestone Reached for Prostate Cancer Trial

Clarity Pharmaceuticals Ltd Announces First Patient Treated in Therapeutic Prostate Cancer Trial

Clarity Pharmaceuticals Ltd, Annual General Meeting, Nov 24, 2022

Consensus forecasts updated

Clarity Pharmaceuticals Ltd Successfully Imaged Its First Participants in the Diagnostic 64 CU SAR-Bombesin Trial (Bop) for Patients with PSMA-Negative Prostate Cancer in Australia

Clarity Pharmaceuticals Appoints Jeffrey Norenberg as Chief Scientific Officer

Clarity Strengthens Protection of the SAR-bisPSMA Product with Granting of China Patent

Clarity Pharmaceuticals Announces Recruitment Opens for Phase II Trial in Prostate Cancer

Consensus revenue estimates increase by 182%

Forecast to breakeven in 2025

Clarity Pharmaceuticals Ltd Advances to Cohort 3 of the Cl04 Trial of Sartate in Paediatric Neuroblastoma

Companies Like Clarity Pharmaceuticals (ASX:CU6) Are In A Position To Invest In Growth

Clarity Pharmaceuticals Announces Diagnostic 64 Cu SAR-Bombesin Trial (BOP) for Patients with Prostate Cancer Is Open for Recruitment in Australia

Clarity Pharmaceuticals Announces Recruitment Complete for Diagnostic Prostate Cancer Trial

Clarity Pharmaceuticals Ltd Appoints Louise Emmett to Its Scientific Advisory Board

Non-Executive Director recently bought AU$53k worth of stock

マネジメント基準チェック /24